Pediatric Exclusivity

Pediatric exclusivity under the Best Pharmaceuticals for Children Act (BPCA) is a regulatory incentive that rewards drug companies for conducting pediatric clinical studies by extending their intellectual property protection: THE BPCA FRAMEWORK: the Best Pharmaceuticals for Children Act (originally enacted as part of the FDA Modernization Act in 1997, re-enacted in 2002, and made permanent in 2012) addresses the historical problem that most drugs were approved only in adults; children's dosing was often extrapolated from adult studies; pediatric patients often received drugs with unknown pediatric pharmacokinetics and safety profiles; to encourage pediatric drug development, Congress created an incentive: conduct FDA-requested pediatric studies and receive a 6-month extension of IP protection; THE WRITTEN REQUEST: the FDA issues a written request to an NDA or BLA holder asking them to conduct specific pediatric studies; the written request identifies: the indication to study; the age groups to be studied; the study design (safety; pharmacokinetics; efficacy as appropriate); the endpoints required; the FDA can issue written requests proactively (without waiting for the sponsor to ask); sponsors can also request that FDA issue a written request for their drug; WHAT TRIGGERS THE 6-MONTH EXTENSION: the sponsor must submit reports of the pediatric studies to FDA; the studies must be conducted IN ACCORDANCE WITH the terms of the written request; FDA must accept the submission as meeting the written request requirements; the 6-month exclusivity is then granted; WHAT IS NOT REQUIRED TO GET THE EXTENSION: pediatric efficacy is NOT required — the drug can fail to show pediatric benefit; pediatric safety is NOT required to be fully established — the extension is for attempting to generate data; the drug does NOT need to receive a pediatric labeling change to get the extension; the requirement is COMPLETION OF THE STUDIES as requested, not a particular outcome; IMPORTANT DISTINCTION: FDA will issue a determination letter accepting or rejecting whether the sponsor has responded to the written request; rejection means no extension; acceptance (even for negative studies) means the extension is granted.

The pediatric exclusivity extension is unusually broad — it applies to ALL unexpired patents and ALL unexpired regulatory exclusivity periods simultaneously: SCOPE OF THE EXTENSION — WHAT IT COVERS: ORANGE BOOK PATENTS: every patent listed in the Orange Book for the NDA product that has not yet expired receives a 6-month extension added to its expiration date; the extension applies to the patent term, not the exclusivity period — the actual patent expires 6 months later; REGULATORY EXCLUSIVITY PERIODS: all unexpired regulatory exclusivity periods are extended by 6 months: 5-year NCE exclusivity → becomes 5.5 years; 3-year clinical exclusivity → becomes 3.5 years; 7-year orphan drug exclusivity → becomes 7.5 years; biologics 12-year exclusivity → becomes 12.5 years; TIMING LIMITATION — MUST BE UNEXPIRED: the extension applies only to exclusivity periods and patents that have NOT YET EXPIRED at the time the pediatric exclusivity is granted; a patent or exclusivity that expired before the extension was granted CANNOT be retroactively extended; THE PRACTICAL SIGNIFICANCE: timing matters — completing the studies and submitting them BEFORE key patents and exclusivities expire is essential to capture the benefit; sponsors should plan study completion with the patent expiry calendar in mind; STACKING EXAMPLE — NCE DRUG WITH STRONG PATENT PORTFOLIO: original compound patent: 15 years remaining at time of exclusivity grant → extends to 15.5 years; formulation patent: 8 years remaining → extends to 8.5 years; NCE 5-year exclusivity: still active → extends to 5.5 years; all three receive the extension simultaneously; STACKING EXAMPLE — ORPHAN DRUG: 7-year orphan exclusivity with 4 years remaining → extends to 4.5 years remaining (original 7 + 6 months); any unexpired Orange Book patents also get 6 months; STACKING EXAMPLE — BIOLOGICS: 12-year biologics exclusivity with 3 years remaining → extends to 3.5 years remaining; biosimilar applicants cannot file the full BLA until the extended date; COMMERCIAL VALUE: for a major drug with $2 billion in annual US sales, 6 additional months = approximately $1 billion in additional revenue; the cost of conducting FDA-requested pediatric studies (typically $10-50 million) is far outweighed by the commercial value of the extension.

BPCA and PREA (Pediatric Research Equity Act) are two distinct statutory frameworks that together govern pediatric drug development — one is voluntary with an incentive, the other is mandatory: BPCA (Best Pharmaceuticals for Children Act): VOLUNTARY: the FDA issues a written request; the sponsor CHOOSES whether to conduct the studies; if the sponsor conducts the studies as requested and completes them to FDA's satisfaction, the sponsor receives the 6-month exclusivity extension; the sponsor can decline — no obligation to respond; INCENTIVE-BASED: the only consequence of declining is forgoing the 6-month extension; no penalty for not responding to a written request; applies to drugs that are already approved and where pediatric use is off-label or under-studied; PREA (Pediatric Research Equity Act, enacted 2003, made permanent 2012): MANDATORY: under 21 U.S.C. § 355c, when a sponsor submits an NDA or supplement for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration, FDA can require that pediatric assessments be conducted as part of the NDA; applies to drugs likely to be used in pediatric populations; CONSEQUENCE: failure to comply can result in refusal to approve the NDA; the sponsor MUST submit or obtain a waiver/deferral; WAIVERS: FDA can waive PREA requirements when: the drug is unlikely to be used in a substantial number of pediatric patients; the evidence strongly suggests the drug will be ineffective or unsafe in children; studies are impossible or highly impracticable; DEFERRALS: FDA can defer the pediatric assessment to after the initial adult approval; the deferral is time-limited; THE KEY DIFFERENCE: BPCA: voluntary + 6-month extension incentive; PREA: mandatory + no 6-month extension; a sponsor required to do pediatric studies under PREA does NOT get the 6-month extension for complying; to get the extension, the sponsor needs a SEPARATE written request under BPCA; it is possible (and common) to satisfy both: do the PREA studies AND submit them in response to a BPCA written request, getting credit under both frameworks; PRACTICAL ADVICE: sponsors should monitor for FDA written requests; proactively request written requests when studying drugs in pediatric populations; plan study timelines with patent expiry dates in mind to capture the extension before key patents expire.

The EU and other major jurisdictions have created their own pediatric incentive frameworks that differ from the US BPCA in important ways: EU PAEDIATRIC REGULATION (EC No. 1901/2006): WHAT IT IS: requires that pharmaceutical companies submit pediatric investigation plans (PIPs) as part of marketing authorization applications; the EU took a stricter approach than the US — pediatric development is MANDATORY for most new drugs; the reward for complying is an extension of the Supplementary Protection Certificate (SPC); EU SPC EXTENSION: the EU Supplementary Protection Certificate (SPC) extends patent protection for up to 5 years beyond the 20-year patent term (to compensate for time spent in regulatory approval); if a drug completes its PIP and receives a pediatric indication or labeling change, the SPC is extended by 6 months; COMPARISON WITH US: EU: pediatric development is MANDATORY under PIP; the SPC + 6-month extension is the incentive; applies to SPC only (not to all patents like in US); US: BPCA is voluntary + written request; 6-month extension applies to ALL unexpired patents AND all exclusivities simultaneously; scope of US extension is broader (applies to more IP instruments); EU ORPHAN DRUG PEDIATRIC EXTENSION: if an orphan drug completes its PIP, the EU orphan 10-year exclusivity extends by 2 years (to 12 years); this 2-year extension (not 6 months) is much larger than the EU SPC extension and represents a major commercial incentive for rare pediatric diseases; JAPAN: Japan's Pharmaceutical and Medical Device Act includes pediatric development incentives; re-examination periods can be extended for drugs that include pediatric labeling; specific incentives vary by drug class and indication; GLOBAL PEDIATRIC CONSISTENCY: the ICH E11 and E11(R1) guidelines provide harmonized guidance for pediatric drug development across US, EU, and Japan; FDA, EMA, and PMDA collaborate on pediatric written requests and PIPs through the Pediatric Cluster under the ICH; FDA-EMA pediatric data sharing: FDA and EMA share pediatric data (but not the marketing authorization applications themselves); STRATEGIC GLOBAL APPROACH: for major drugs, sponsors should coordinate US (BPCA written request) + EU (PIP) + Japan (pediatric development plan) simultaneously; completing all three frameworks maximizes global IP protection extensions; the combined IP value of US 6-month extension + EU SPC 6-month + EU orphan 2-year extension can be several billion dollars for high-value drugs.